Peter Keller

Biography

Mr. Keller joined Selecta Biosciences, Inc. from Abbott Laboratories in 2011. In addition to his role as Chief Business Officer, Mr. Keller leads Selecta’s gene therapy programs. After the acquisition of Solvay Pharmaceuticals in 2010 by Abbott Laboratories, he led the integration process for five R&D and manufacturing facilities in Europe. Before the acquisition, Mr. Keller was Vice President, Head of Mergers & Acquisitions and Alliance Management at Solvay Pharmaceuticals, where he negotiated license and acquisition agreements in various therapeutic areas such as vaccines, neurology and cardiology. He was the lead negotiator for the $1.5 billion fenofibrate alliance between Solvay Pharmaceuticals and Abbott Laboratories and was instrumental in the $6.2 billion acquisition of Solvay Pharmaceuticals by Abbott Laboratories

Research Interest

Molecular Biology and Molecular Genetics